SCHEMBL5135779

SCHEMBL5135779

CCCCN(CCCCCCO)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.44
ALDH1A1 P00352 11/20 0.43
KDM4E B2RXH2 10/20 0.43
HPGD P15428 10/20 0.43
HSD17B10 Q99714 10/20 0.43
CYP3A4 P08684 7/20 0.43
C5AR1 P21730 1/20 0.43
PDE4B Q07343 2/20 0.40
HDAC1 Q13547 1/20 0.39
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137349 0.93 C5AR1 (0.43) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL650694 0.92 TSHR (0.51) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL649161 0.85 C5AR1 (0.47) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5136516 0.85 C5AR1 (0.43) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5135312 0.85 C5AR1 (0.46) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5135685 0.85 FAAH (0.52) TSHRALDH1A1KDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL648480 0.84 C5AR1 (0.46) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5137489 0.83 C5AR1 (0.48) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL4774335 0.83 C5AR1 (0.44) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5074963 0.83 C5AR1 (0.43) TSHRALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed